Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study

Abstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN,...

Full description

Bibliographic Details
Main Authors: Nahid Hashemi Madani, Faramarz Ismail-Beigi, Hossein Poustchi, Mahdi Nalini, Sadaf G. Sepanlou, Mojtaba Malek, Mohammad Amin Abbasi, Alireza Khajavi, Mohammad E. Khamseh, Reza Malekzadeh
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cardiovascular Disorders
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12872-020-01390-8
id doaj-347732ae67b64224ab31e1d817d5c30d
record_format Article
spelling doaj-347732ae67b64224ab31e1d817d5c30d2020-11-25T03:25:08ZengBMCBMC Cardiovascular Disorders1471-22612020-03-0120111110.1186/s12872-020-01390-8Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort studyNahid Hashemi Madani0Faramarz Ismail-Beigi1Hossein Poustchi2Mahdi Nalini3Sadaf G. Sepanlou4Mojtaba Malek5Mohammad Amin Abbasi6Alireza Khajavi7Mohammad E. Khamseh8Reza Malekzadeh9Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Case Western Reserve University, School of MedicineLiver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical SciencesDigestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesDigestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesResearch Center for Prevention of Cardiovascular Diseases, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Student Research Committee, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical ScienceEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS)Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical SciencesAbstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of MACE as well as individual MACE components. Methods This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP on occurrence of MACE as the primary endpoint. Results Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19–4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04–4.07; p, 0.000) or HTN + DLP (HR, 2.98; 95% CI, 1.89–4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP, or both was also associated with an increase in the incidence of MACE. Conclusion IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP, can be associated with an increase in the risk for CVD- death.http://link.springer.com/article/10.1186/s12872-020-01390-8Dyslipidemia (DLP)Hypertension (HTN)Impaired fasting glucose (IFG)Major adverse cardiovascular events (MACE)Pre-diabetes (pre-DM)
collection DOAJ
language English
format Article
sources DOAJ
author Nahid Hashemi Madani
Faramarz Ismail-Beigi
Hossein Poustchi
Mahdi Nalini
Sadaf G. Sepanlou
Mojtaba Malek
Mohammad Amin Abbasi
Alireza Khajavi
Mohammad E. Khamseh
Reza Malekzadeh
spellingShingle Nahid Hashemi Madani
Faramarz Ismail-Beigi
Hossein Poustchi
Mahdi Nalini
Sadaf G. Sepanlou
Mojtaba Malek
Mohammad Amin Abbasi
Alireza Khajavi
Mohammad E. Khamseh
Reza Malekzadeh
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
BMC Cardiovascular Disorders
Dyslipidemia (DLP)
Hypertension (HTN)
Impaired fasting glucose (IFG)
Major adverse cardiovascular events (MACE)
Pre-diabetes (pre-DM)
author_facet Nahid Hashemi Madani
Faramarz Ismail-Beigi
Hossein Poustchi
Mahdi Nalini
Sadaf G. Sepanlou
Mojtaba Malek
Mohammad Amin Abbasi
Alireza Khajavi
Mohammad E. Khamseh
Reza Malekzadeh
author_sort Nahid Hashemi Madani
title Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
title_short Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
title_full Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
title_fullStr Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
title_full_unstemmed Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
title_sort impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the golestan cohort study
publisher BMC
series BMC Cardiovascular Disorders
issn 1471-2261
publishDate 2020-03-01
description Abstract Background Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of MACE as well as individual MACE components. Methods This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP on occurrence of MACE as the primary endpoint. Results Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19–4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04–4.07; p, 0.000) or HTN + DLP (HR, 2.98; 95% CI, 1.89–4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP, or both was also associated with an increase in the incidence of MACE. Conclusion IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP, can be associated with an increase in the risk for CVD- death.
topic Dyslipidemia (DLP)
Hypertension (HTN)
Impaired fasting glucose (IFG)
Major adverse cardiovascular events (MACE)
Pre-diabetes (pre-DM)
url http://link.springer.com/article/10.1186/s12872-020-01390-8
work_keys_str_mv AT nahidhashemimadani impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT faramarzismailbeigi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT hosseinpoustchi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT mahdinalini impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT sadafgsepanlou impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT mojtabamalek impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT mohammadaminabbasi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT alirezakhajavi impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT mohammadekhamseh impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
AT rezamalekzadeh impairedfastingglucoseandmajoradversecardiovasculareventsbyhypertensionanddyslipidemiastatusthegolestancohortstudy
_version_ 1724598779271708672